DEA Proposes Changes to Drug Quota Applications
Published Date: 5/20/2026
Proposed Rule
Summary
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
Analyzed Economic Effects
5 provisions identified: 1 benefits, 3 costs, 1 mixed.
New Quota Application Timeline Reporting
If you are a bulk or non-bulk manufacturer applying for DEA quotas, you must provide new production-timeline details on quota applications (DEA Form 189 for bulk manufacturers; DEA Form 250 for non-bulk manufacturers). DEA lists the required items: desired individual manufacturing quota (bulk only), time to start production after receiving DEA's quota letter, time to receive API after quota letter (procurement), time to perform the production cycle, time to ship finished goods to the next registrant, supplier of the basic class/chemical (if from another registrant), and any additional relevant factors.
Better Data to Prevent Drug Shortages
DEA says the new application information and subcategory changes will give the agency better visibility into manufacturing cycles and domestic vs. export use, enabling DEA to adjust quotas more quickly to anticipate and help prevent drug shortages that affect medical and scientific needs.
Domestic vs. Export Quota Split
DEA will split certain quota subcategories so manufacturers must state whether quota is for domestic use or for lawful export. The rule bifurcates 'Quota for Commercial Sale', 'Quota for Product Development', and 'Quota for Packaging/Repackaging and Labeling/Relabeling' into domestic and export subcategories (e.g., 'Quota for Domestic Commercial Sale' and 'Quota for Commercial Manufacturing for Export').
Estimated Time and Dollar Burden
DEA estimates the new information will add about 20 minutes per DEA Form 189 or 250 to complete, with a loaded median hourly cost of $89.42 for a purchasing manager, producing an estimated per-application cost of $29.81. Using 2022 application counts (875 Form 189 and 2,514 Form 250), DEA estimates an annual total cost of $101,026.
Small-Entity Impact Finding
DEA certifies under the Regulatory Flexibility Act that the proposed rule will not have a significant economic impact on a substantial number of small entities. DEA estimates the rule would affect 38 of 635 small entities in NAICS 325411 and 272 of 1,080 small entities in NAICS 325412, with estimated economic impacts of 0.095% and 0.022% of annual receipts for those industries, respectively.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-16665, Exempt Chemical Preparations Under the Controlled Substances Act
The applications for exempt chemical preparations received by the Drug Enforcement Administration between March 1, 2026, and June 30, 2026, as listed below, were accepted for filing and have been approved or denied as indicated. This publication addresses preparations through June 30, 2026, that were not included in previous Federal Register notices, and it does not affect preparations that have been previously published.
2026-16413, Schedules of Controlled Substances: Temporary Placement of O-Desmethyltramadol in Schedule I
The Drug Enforcement Administration issues this temporary order to schedule O-desmethyltramadol (other names: O-DSMT; desmetramadol; 3-[(1R,2R)-2-[(dimethylamino)methyl]-1- hydroxycyclohexyl]phenol), including its isomers, esters, ethers, salts, and salts of isomers, esters and ethers, in schedule I of the Controlled Substances Act. DEA bases this action on a finding that placing O-DSMT in schedule I is necessary to avoid an imminent hazard to public safety. This order imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle O-DSMT.
2026-16375, Schedules of Controlled Substances: Rescheduling of Suvorexant, Lemborexant, and Daridorexant From Schedule IV Into Schedule V
The Drug Enforcement Administration proposes to transfer suvorexant ([(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4- diazepan-1-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone), lemborexant ((1R,2S)-2-[(2,4-dimethylpyrimidin-5-yl)oxymethyl]-2-(3-fluorophenyl)- N-(5-fluoropyridin-2-yl)cyclopropane-1-carboxamide), and daridorexant ([(2S)-2-(5-chloro-4-methyl-1H-benzimidazol-2-yl)-2-methylpyrrolidin-1- yl]-[5-methoxy-2-(triazol-2-yl)phenyl]methanone) from schedule IV to schedule V of the Controlled Substances Act. If finalized, this action would impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule V controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle suvorexant, lemborexant, and daridorexant.
2026-15624, Amendment to 3,4-MDP-2-P Methyl Glycidic Acid, a List I Chemical
The Drug Enforcement Administration is proposing to modify the listing of the list I chemical 3,4-MDP-2-P methyl glycidic acid (also known as PMK glycidic acid) to include esters of 3,4-MDP-2-P methyl glycidic acid, not listed elsewhere in the Controlled Substances Act (CSA), as list I chemicals under the CSA. The current listing of 3,4- MDP-2-P methyl glycidic acid includes its salts, optical and geometric isomers, and salts of isomers. DEA proposes the new listing to read as follows: 3,4-MDP-2-P methyl glycidic acid (PMK glycidic acid) and its esters, not listed elsewhere in the CSA, its optical and geometric isomers, its salts, salts of its optical and geometric isomers, salts of its esters, not listed elsewhere in the CSA, and any combination thereof, whenever the existence of such is possible.
2026-15328, Joan Rubinger, N.P.; Decision and Order
Previous / Next Documents
Previous: 2026-10086, Extending the Compliance Deadline for the PFOA and PFOS Maximum Contaminant Levels
The EPA is giving water systems more time to meet safety rules for two harmful chemicals, PFOA and PFOS, by extending the deadline from April 2029 to April 2031 if they ask for it. This helps water providers get ready without rushing, keeping our drinking water safe. The EPA wants your thoughts and will hold a public hearing in July 2026 to hear from everyone.
Next: 2026-10161, Significant New Use Rules on Certain Chemical Substances (26-2); Extension of Comment Period
The EPA is giving folks more time to share their thoughts on new rules about certain chemicals. If you make, import, or use these chemicals in new ways, you have to tell the EPA 90 days before starting. The comment deadline is now July 10, 2026, so don’t miss your chance to speak up!